Systemic chemotherapy in addition to CRS-HIPEC for colorectal peritoneal metastases: A critical systematic review on the impact on overall survival

Teun B M van den Heuvel*, Robin J Lurvink, Koen P B Rovers, Irene E G van Hellemond, Ignace H J T de Hingh*

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

Abstract

In patients with resectable colorectal peritoneal metastases, it is unclear whether systemic chemotherapy, in addition to cytoreductive surgery-hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), improves overall survival (OS). This systematic review of 12 retrospective studies involving 3721 patients aimed to summarize the available evidence. Contradictory results were found regarding the effectiveness of neoadjuvant, adjuvant, and perioperative systemic therapies on OS, with a high risk of bias. Available evidence remains inconclusive, stressing the need for prospective, randomized trials, like the ongoing Dutch CAIRO6-trial.
Original languageEnglish
Number of pages12
JournalJournal of surgical oncology
DOIs
Publication statusPublished - 11 Sept 2024

Keywords

  • CRS-HIPEC
  • colorectal cancer
  • overall survival
  • peritoneal metastases
  • systematic review
  • systemic chemotherapy

Fingerprint

Dive into the research topics of 'Systemic chemotherapy in addition to CRS-HIPEC for colorectal peritoneal metastases: A critical systematic review on the impact on overall survival'. Together they form a unique fingerprint.

Cite this